Molnupiravir
The World Health Organization (WHO) modified its Covid-19 therapy guidelines on March 2nd to add molnupiravir, an antiviral medication, for patients with non-severe Covid-19 who are at high risk of hospitalization.
Elderly Patients who are unvaccinated, have a weakened immune system, or suffer from certain chronic diseases are at the biggest risk of being admitted to the hospital.
However, due to potential hazards, the expert panel advised against giving the medicine to young and healthy individuals, such as children, as well as pregnant and breastfeeding mothers.
Even though the Indian pharmaceuticals regulator approved molnupiravir for limited emergency use in December, the national Covid-19 task committee is currently debating whether to include it in the regular Covid-19 treatment protocol due to safety concerns.
